美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

2倍做多NVO ETF-Defiance

12.39

-0.5900-4.55%

盤後：12.36-0.0300-0.24%19:34 EDT

成交量：37.25萬

成交額：460.34萬

市值：3,243.83萬

市盈率：- -

高：12.63

開：12.48

低：12.20

收：12.98

52周最高：36.00

52周最低：9.23

股本：261.81萬

流通股本：261.81萬

量比：1.13

換手率：14.23%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

美銀首席執行官：公司每年為員工支出2.5億美元用於報銷GLP-1減重藥物

环球市场播报

相差百億美元！全球第一大藥王與第二大藥王銷售差距在拉大

二季度利潤亮眼股價卻下跌近6% 口服減重藥能撐起諾和諾德的中長期預期嗎？

每日经济新闻

諾和諾德：海牙法院針對 Ceban 下達臨時禁令。

諾和諾德贏得荷蘭法院禁令，保護患者免受未經批准的非法複方司美格魯肽鼻噴霧劑的侵害。

國產藥加速追趕減重明星賽道進入「群雄逐鹿」時代

諾和諾德首席執行官：相較於注射劑，口服版 Wegovy 的市場需求之高，讓我們愈發感到意外。

諾和諾德股價下跌6.8%，觸及盤中低點。

諾和諾德：目前美國市場索馬魯肽注射劑Wegovy的價格走勢與我們年初啓動定價時一致。

諾和諾德首席財務官表示：我們推進全公司轉型以實現80億丹麥克朗成本節約目標的進度，目前已超前於計劃。

諾和諾德股價跌勢擴大，目前跌幅已超5%，年初至今累計下跌10%。

諾和諾德(NVO.US)首席執行官：我們將在資本市場日上詳細介紹如何加速早期資產和早期科學的推進。

諾和諾德首席執行官：進行合併或收購的企業目前都陷入了某種困境，它們已經無法再開展創新了。

諾和諾德CEO力挺Wegovy口服片劑，售價下行拖累銷售，公司股價走低

环球市场播报

諾和諾德首席執行官：目前無意開展重大轉型式收購交易。

諾和諾德首席執行官：公司不會討論進一步降低藥品折扣。

諾和諾德Q2業績超預期、上調全年指引卻難掩隱憂

諾和諾德CEO業績展望上調，然研發管線隱憂未散，遭投資者質詢

諾和諾德首席財務官：我們目前沒有任何在未來推行成本削減的計劃。

諾和諾德首席執行官：減肥藥Wegovy口服劑型很快將在德國上市。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/NVOX/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":12.39,"timestamp":1789156800000,"preClose":12.98,"halted":0,"volume":372450,"hourTrading":{"tag":"盘后","latestPrice":12.36,"preClose":12.39,"latestTime":"19:34 EDT","volume":1741,"amount":21555.3422,"timestamp":1789169681481,"change":-0.03,"changeRate":-0.002421,"amplitude":0.003228},"delay":0,"changeRate":-0.04545454545454544,"floatShares":2618100,"shares":2618100,"eps":0,"marketStatus":"休市中","change":-0.59,"latestTime":"09-11 16:00:00 EDT","open":12.48,"high":12.625,"low":12.195,"amount":4603397.0814,"amplitude":0.033128,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":12.98,"sharesOutstanding":4098101,"nav":12.96,"aum":33930588.96,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":12.45,"preClose":12.98,"latestTime":"09:23 EDT","volume":24165,"amount":304064.23194,"timestamp":1789132997082,"change":-0.53,"changeRate":-0.040832,"amplitude":0.033128},"postHourTrading":{"tag":"盘后","latestPrice":12.36,"preClose":12.39,"latestTime":"19:34 EDT","volume":1741,"amount":21555.3422,"timestamp":1789169681481,"change":-0.03,"changeRate":-0.002421,"amplitude":0.003228},"volumeRatio":1.128144556689369,"impliedVol":0.6704,"impliedVolPercentile":0.192},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2618100,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.128144556689369,"shares":2618100,"dividePrice":0,"high":12.625,"amplitude":0.033128,"preClose":12.98,"low":12.195,"week52Low":9.23,"pbRate":"--","week52High":36,"institutionHeld":0,"latestPrice":12.39,"eps":0,"divideRate":0,"volume":372450,"delay":0,"ttmEps":0,"open":12.48,"prevYearClose":21.89,"prevWeekClose":14.57,"prevMonthClose":13.84,"prevQuarterClose":16.05,"fiveDayClose":15.19,"twentyDayClose":14.6,"sixtyDayClose":13.45},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657529184","title":"美銀首席執行官：公司每年為員工支出2.5億美元用於報銷GLP-1減重藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2657529184","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657529184?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 00:44","pubTimestamp":1785948240,"startTime":"0","endTime":"0","summary":"美银首席执行官布莱恩莫伊尼汉周三接受采访称，美国银行每年花费逾 2.5 亿美元，承担员工使用 GLP-1 减重药物的费用。根据莫伊尼汉给出的数据，美银每年为约 21.1 万名员工预留合计超 20 亿美元医疗预算；仅 GLP-1 药物一项，如今就占到全部医疗开支的约 13%。“我们在 GLP-1 药物上投入大约 2.5 亿美元甚至更多，而四五年前这项支出还是零。”这家全美资产规模第二大的银行，同时依托自身庞大的采购体量，与药企、药房福利管理机构谈判压低药价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-06/doc-inimhyac1066977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVOH","NVOX","GLP","JDOC","BK4590","BK4144","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657998525","title":"相差百億美元！全球第一大藥王與第二大藥王銷售差距在拉大","url":"https://stock-news.laohu8.com/highlight/detail?id=2657998525","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657998525?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 22:54","pubTimestamp":1785941698,"startTime":"0","endTime":"0","summary":"礼来的替尔泊肽与诺和诺德的司美格鲁肽，在2025年分别成为全球销售额第一大、第二大药物，但这两大GLP-1药物之间的销售额差距在拉大。8月5日晚间，礼来公布的半年报显示，2026年上半年，替尔泊肽（降糖适应证产品Mounjaro和减重适应证产品Zepbound）合计收入达到276.93亿美元，同比大增近88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832918043.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832918043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1868836591.USD","JDOC","LU0820561909.HKD","LU1629891620.HKD","LU2237443465.HKD","LU1366192091.USD","IE00BK4W5L77.USD","LU2491049909.HKD","TMED","LU0106261372.USD","RXL","LU1868836757.USD","SG9999013999.USD","LU0683600562.USD","BK4533","LU1232071149.USD","LU1280957306.USD","LU2237443549.SGD","LU0345770308.USD","LU0354030511.USD","LU1979441026.SGD","XLV","LU2746668974.SGD","IE00BKPKM429.USD","IE0005OL40V9.USD","SG9999018857.SGD","IE00BFSS7M15.SGD","IE00BZ1G4Q59.USD","LU0234572021.USD","LU2324357040.USD","LU2471134879.HKD","LU2089284900.SGD","LU2089283258.USD","LU0353189763.USD","NVOX","LU2756315664.SGD","ELIS","LU2471134796.USD","BK4588","LLYZ","LU0964807845.USD","LU0385154629.USD","LU0417517546.SGD","LU2168564495.EUR","LU2456880835.USD","LU0079474960.USD","LU2471134952.CNY","IE00B4JS1V06.HKD","LU0061475181.USD","SGXZ51526630.SGD","WDNA","IE00BKVL7J92.USD","LLY","AGNG","LU0689472784.USD","LU1720051017.SGD","LU2896262040.SGD","LU0133085943.USD","LU1814569148.SGD","LU0471298777.SGD","BK4516","IE00B7KXQ091.USD","SGXZ31699556.SGD","LU0154236417.USD","THNR","LU0320765992.SGD","LLYX","MHIP","LU2462591350.SGD","LU0820562030.AUD","BK4534","LU1035775433.USD","IE00BJT1NW94.SGD","FHLC","LU2357305700.SGD","FTXH","LU0345770993.USD","LU2023250504.SGD","LU0238689110.USD","LU1093756325.SGD","LU0354030438.USD","SGXZ99366536.SGD","LU0786609619.USD","LU1057294990.SGD","LU1989771016.USD","LU2462157665.USD","LU2089984988.USD","BK4581","LU0432979614.USD","LU1623119135.USD","PJP","SG9999014880.SGD","LU1069344957.HKD","LU2750360997.AUD","LU0466842654.USD","LU2746668461.USD","IE00BJJMRZ35.SGD","LU1974910355.USD","LU0096364046.USD","LU2756315318.SGD","LU1548497426.USD","LU1323610961.USD","LU1868837300.USD","LU0316494557.USD","LU2111349929.HKD","LU0943347566.SGD","IE00BFSS8Q28.SGD","SG9999015952.SGD","IE00BJJMRX11.SGD","LU1291159041.SGD","LU2023251221.USD","LU0203202063.USD","LU1064131342.USD","LU2168564065.EUR","LU0882574055.USD","IE00B1XK9C88.USD","LU0256863811.USD","CANC","LU2271345857.HKD","SGXZ57979304.SGD","LU2168564149.EUR","SG9999018865.SGD","LU0471298694.HKD","LU0820561818.USD","LU0094547139.USD","LU0203201768.USD","SG9999015978.USD","IE00BJJMRY28.SGD","MEDX","LU0289739699.SGD","LU2361044949.HKD","IE0001KFT4U8.USD","LU0640476718.USD","LU2106854487.HKD","IE00B1BXHZ80.USD","LU0889565916.HKD","GDOC","LU0787776722.HKD","OZEM","LU1712237335.SGD","BK4532","LU0225283273.USD","LU2236285917.USD","LU0708995401.HKD","LU2264538146.SGD","IE00BKDWB100.SGD","LU1127390331.HKD","SG9999001176.USD","LU2602419157.SGD","LU0672654240.SGD","LU0198837287.USD","IE0004445015.USD","LU2168564222.USD","IE00BK4W5M84.HKD","LU0174119429.USD","LU0323591593.USD","GB00BDT5M118.USD","PPH","LU2491050071.SGD","IXJ","MEDI","LU1551013425.SGD","LU2360106947.USD","SGXZ81514606.USD","LU0006306889.USD","LU1917777945.USD","LU2552382058.USD","IE0004445239.USD","VHT","LU2168563687.JPY","LU2361045086.USD","IE00B4R5TH58.HKD","NVOH","LU0109391861.USD","SG9999014898.SGD","LU1868837136.USD","LU2417539215.USD","SG9999014906.USD","LU0109394709.USD","TRUH","SG9999001176.SGD","LU0210536198.USD","IHE","LU2087625088.SGD","LU0320765059.SGD","LU1551013342.USD","SG9999015986.USD","BK4007","LU2063271972.USD","LU0097036916.USD","SG9999015945.SGD","LU2108987350.USD","LU0456855351.SGD","HRTS","LU1988902786.USD","IE00BFTCPJ56.SGD","LU1804176565.USD","LU2468319806.SGD","LU2213496289.HKD","LU0256863902.USD","IE00BJLML261.HKD","LU2552382132.HKD","LU0823434740.USD","LU2237443382.USD","SG9999014914.USD","LU0823416689.USD","LU0122379950.USD","LU2237443895.HKD","LU0353189680.USD","LU1061106388.HKD","LU0058720904.USD","ELIL","ILDR","CURE","LU2471134523.USD","IE0009355771.USD","LU0158827781.USD","IE00B775H168.HKD","IE00BWXC8680.SGD","LU0266013472.USD","NVO","IE0002141913.USD","LU2237438978.USD","LU2750360641.GBP","LU2552382215.SGD","LU0823434583.USD","LU2491050154.USD","LU2237443978.SGD","SG9999017495.SGD","LU2361044865.SGD","LU1983299246.USD","LU1023059063.AUD","LU2028103732.USD","LLII","LU2265009873.SGD","LU2023250330.USD","LU2461242641.AUD","BK4599","LU1720051108.HKD","BK4585","LU1093756168.USD","LU1868836914.USD","LU0114720955.EUR","LU1145028129.USD","LU2112291526.USD","LU1267930730.SGD","LU2237443622.USD","LU0158827948.USD","LU2211815571.USD","IYH","IE00BN29S564.USD","IE00B2B36J28.USD","LU0882574139.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657528844","title":"二季度利潤亮眼股價卻下跌近6% 口服減重藥能撐起諾和諾德的中長期預期嗎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657528844","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657528844?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:50","pubTimestamp":1785937800,"startTime":"0","endTime":"0","summary":"二季度利润超预期、上调全年指引，却遭遇美股下跌6%；口服GLP-1药物Wegovy商业化取得突破，但下一代核心CagriSema两次头对头败给礼来替尔泊肽。在千亿美元减肥药赛道，诺和诺德正经历从“霸主”到激烈博弈的转变，增长的希望与风险高度集中于口服GLP1这条路线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832855655.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832855655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1093756325.SGD","IE00BKVL7J92.USD","BK4532","OZEM","BK4007","LU0154236417.USD","NVOH","IE00BZ1G4Q59.USD","NVO","PPH","BK4585","NVOX","LU1093756168.USD","THNR","BK4599","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657238540","title":"諾和諾德：海牙法院針對 Ceban 下達臨時禁令。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657238540","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657238540?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:44","pubTimestamp":1785937442,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","BK4007","NVOX","BK4599","BK4585","IE00BZ1G4Q59.USD","THNR","LU0154236417.USD","NVOH","LU1093756325.SGD","LU1093756168.USD","IE00BKVL7J92.USD","NVO","OZEM","PPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540463","title":"諾和諾德贏得荷蘭法院禁令，保護患者免受未經批准的非法複方司美格魯肽鼻噴霧劑的侵害。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657540463?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:43","pubTimestamp":1785937380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["OZEM","LU0154236417.USD","NVO","THNR","IE00BKVL7J92.USD","BK4588","BK4585","BK4532","BK4007","LU1093756168.USD","PPH","BK4599","NVOH","NVOX","LU1093756325.SGD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547441","title":"國產藥加速追趕 減重明星賽道進入「群雄逐鹿」時代","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547441","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657547441?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:07","pubTimestamp":1785935232,"startTime":"0","endTime":"0","summary":"新华财经上海8月5日电2026年，我国“体重管理年”三年行动进入收官之年。当前，全民体重管理意识和技能显著提升，健康生活方式更加普及，部分人群体重异常状况得到改善。体重管理催生了减重经济。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832808212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832808212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["RSPH","JDOC","NVOH","THNR","NVOX","NVOC","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657073541","title":"諾和諾德首席執行官：相較於注射劑，口服版 Wegovy 的市場需求之高，讓我們愈發感到意外。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657073541","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657073541?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 20:04","pubTimestamp":1785931485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","OZEM","PPH","NVOX","LU0154236417.USD","LU1093756168.USD","BK4599","NVO","LU1093756325.SGD","BK4585","BK4532","THNR","NVOH","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657490745","title":"諾和諾德股價下跌6.8%，觸及盤中低點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657490745","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657490745?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:43","pubTimestamp":1785930191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0154236417.USD","NVOX","THNR","BK4532","IE00BKVL7J92.USD","PPH","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","BK4585","OZEM","BK4588","LU1093756325.SGD","NVOH","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657003549","title":"諾和諾德：目前美國市場索馬魯肽注射劑Wegovy的價格走勢與我們年初啓動定價時一致。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657003549","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657003549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:42","pubTimestamp":1785930157,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","NVOH","OZEM","LU1093756325.SGD","NVOX","BK4532","LU0154236417.USD","BK4585","PPH","THNR","NVO","IE00BKVL7J92.USD","LU1093756168.USD","BK4588","BK4599","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657539549","title":"諾和諾德首席財務官表示：我們推進全公司轉型以實現80億丹麥克朗成本節約目標的進度，目前已超前於計劃。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657539549","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657539549?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:23","pubTimestamp":1785929036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOX","OZEM","LU1093756325.SGD","NVOH","NVO","BK4007","BK4532","IE00BKVL7J92.USD","BK4588","IE00BZ1G4Q59.USD","PPH","THNR","BK4585","LU0154236417.USD","BK4599","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510014","title":"諾和諾德股價跌勢擴大，目前跌幅已超5%，年初至今累計下跌10%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510014?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:06","pubTimestamp":1785924365,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["OZEM","LU0154236417.USD","NVO","THNR","IE00BKVL7J92.USD","BK4588","BK4585","BK4532","BK4007","LU1093756168.USD","PPH","BK4599","NVOH","NVOX","LU1093756325.SGD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657107295","title":"諾和諾德(NVO.US)首席執行官：我們將在資本市場日上詳細介紹如何加速早期資產和早期科學的推進。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657107295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657107295?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:03","pubTimestamp":1785924200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["OZEM","LU0154236417.USD","THNR","BK4585","BK4532","PPH","NVOH","BK4588","NVOX","LU1093756325.SGD","LU1093756168.USD","NVO","IE00BKVL7J92.USD","BK4007","BK4599","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510267","title":"諾和諾德首席執行官：進行合併或收購的企業目前都陷入了某種困境，它們已經無法再開展創新了。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510267","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510267?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 18:01","pubTimestamp":1785924082,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","BK4585","BK4007","OZEM","BK4599","THNR","LU0154236417.USD","PPH","NVOX","NVO","IE00BKVL7J92.USD","LU1093756168.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4588","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657551275","title":"諾和諾德CEO力挺Wegovy口服片劑，售價下行拖累銷售，公司股價走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2657551275","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657551275?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 17:02","pubTimestamp":1785920520,"startTime":"0","endTime":"0","summary":"投资者持续聚焦价格压力、业绩超预期的可持续性，以及 Wegovy 口服片剂能否成为足够强劲的增长引擎，扭转公司增长颓势。诺和诺德坦言，产品降价持续拖累销售收入。不过 CEO 迈克杜斯塔达尔表示，销量持续攀升叠加 Wegovy 口服片剂初期销售表现，证明当前经营策略行之有效。周三交易开盘前，诺和诺德丹麦本土个股年内累计下跌约 5%；尽管 Wegovy 口服片剂上市后股价有所修复，但较 2024 年年中高点仍大跌近 70%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-05/doc-inimhawm4660383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4585","NVOH","LU1093756168.USD","BK4588","NVO","THNR","BK4532","BK4599","PPH","OZEM","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU0154236417.USD","IE00BKVL7J92.USD","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511799","title":"諾和諾德首席執行官：目前無意開展重大轉型式收購交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511799","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511799?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:30","pubTimestamp":1785918656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ1G4Q59.USD","NVO","NVOH","BK4588","NVOX","IE00BKVL7J92.USD","LU1093756325.SGD","PPH","OZEM","THNR","BK4007","BK4585","BK4599","LU1093756168.USD","BK4532","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511459","title":"諾和諾德首席執行官：公司不會討論進一步降低藥品折扣。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511459","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511459?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:26","pubTimestamp":1785918369,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","OZEM","PPH","NVOX","LU0154236417.USD","LU1093756168.USD","BK4599","NVO","LU1093756325.SGD","BK4585","BK4532","THNR","NVOH","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657519148","title":"諾和諾德Q2業績超預期、上調全年指引卻難掩隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2657519148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657519148?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:49","pubTimestamp":1785916176,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德Q2业绩超预期、上调全年指引却难掩隐忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0154236417.USD","NVOX","THNR","BK4532","IE00BKVL7J92.USD","PPH","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","BK4585","OZEM","BK4588","LU1093756325.SGD","NVOH","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2657403515","title":"諾和諾德CEO業績展望上調，然研發管線隱憂未散，遭投資者質詢","url":"https://stock-news.laohu8.com/highlight/detail?id=2657403515","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657403515?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:00","pubTimestamp":1785913213,"startTime":"0","endTime":"0","summary":"“Cagrisema再次令人失望，这可能凸显了诺和诺德面临的最大战略问题。”他表示，这些令人失望的结果将促使诺和诺德加快研发步伐并更加积极地寻求合作机会，而非变得更加谨慎。“这将诺和诺德的研发管线及其稳健性推到了聚光灯下，”AL Sydbank在致客户的报告中表示，并补充道，尽管诺和诺德的业绩本应让投资者松一口气，但这些数据和减值准备却打击了市场情绪。他表示，当务之急是扩大研发管线，同时保持生产效率的纪律性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4S4420LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4599","IE00BKVL7J92.USD","OZEM","THNR","BK4585","BK4588","BK4007","NVOH","PPH","LU0154236417.USD","NVO","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVOX","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657251339","title":"諾和諾德首席財務官：我們目前沒有任何在未來推行成本削減的計劃。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657251339","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657251339?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:28","pubTimestamp":1785911326,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","THNR","BK4532","BK4585","BK4007","LU0154236417.USD","LU1093756325.SGD","NVOX","OZEM","PPH","NVO","BK4599","NVOH","BK4588","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657151338","title":"諾和諾德首席執行官：減肥藥Wegovy口服劑型很快將在德國上市。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657151338","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657151338?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 14:23","pubTimestamp":1785911038,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","PPH","IE00BKVL7J92.USD","BK4585","OZEM","NVOH","LU1093756325.SGD","BK4532","LU0154236417.USD","BK4007","BK4599","IE00BZ1G4Q59.USD","NVO","LU1093756168.USD","NVOX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}